中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2013年
18期
2737-2739
,共3页
心肌病,扩张型%心力衰竭,充血性%卡维地洛%美托洛尔
心肌病,擴張型%心力衰竭,充血性%卡維地洛%美託洛爾
심기병,확장형%심력쇠갈,충혈성%잡유지락%미탁락이
Cardiomyopathy,dilated%Heart failure,congestive%Carvedilol%Metoprolol
目的 比较卡维地洛与美托洛尔治疗扩张型心肌病(DCM)合并心力衰竭的临床疗效.方法 将90例DCM合并心力衰竭患者按照治疗方法不同分为观察组和对照组,各45例.两组均采用利尿、扩血管、强心等药物治疗,对照组加用美托洛尔,观察组加用卡维地洛,连续治疗4～6个月.治疗前后检测和比较两组患者左室射血分数(LVEF)、左室收缩末内径(LVESVI)、左室舒张内径(LVEDVI)、左心室短轴缩短率(FS)、最太峰值血流速度(hCFV)、冠状动脉血流储备(CFR)、血清内皮素(ET)及一氧化氮(NO)含量.结果 观察组治疗后LVEF、LVEDVI、LVESVI、FS、hCFV、CFR、ET、NO分别为(44.0±3.4) ml/m2、(45.2±6.9)mm、(20.9±5.4) mm、(30.4±5.3)、(78.2±31.6)cm/s、(3.12±0.36)、(52.2±5.6) ng/L、(5.2±0.67)μmol/L,均优于对照组治疗后的(37.9 ±3.5)ml/m2、(51.1±7.6)mm、(20.7±6.3) mm、(25.2±7.3)、(70.5±31.8)cm/s、(2.85±0.23)、(63.5±1.8)ng/L、(2.55±0.33)μmol/L(t=8.386、-3.856、-4.487、3.867、-1.152、-4.239、12.887、-23.802,均P≤0.05).结论 卡维地洛是治疗DCM合并心理衰竭的有效药物,能改善患者心功能、冠脉血流储备能力及内皮功能,效果满意,值得在临床推广.
目的 比較卡維地洛與美託洛爾治療擴張型心肌病(DCM)閤併心力衰竭的臨床療效.方法 將90例DCM閤併心力衰竭患者按照治療方法不同分為觀察組和對照組,各45例.兩組均採用利尿、擴血管、彊心等藥物治療,對照組加用美託洛爾,觀察組加用卡維地洛,連續治療4～6箇月.治療前後檢測和比較兩組患者左室射血分數(LVEF)、左室收縮末內徑(LVESVI)、左室舒張內徑(LVEDVI)、左心室短軸縮短率(FS)、最太峰值血流速度(hCFV)、冠狀動脈血流儲備(CFR)、血清內皮素(ET)及一氧化氮(NO)含量.結果 觀察組治療後LVEF、LVEDVI、LVESVI、FS、hCFV、CFR、ET、NO分彆為(44.0±3.4) ml/m2、(45.2±6.9)mm、(20.9±5.4) mm、(30.4±5.3)、(78.2±31.6)cm/s、(3.12±0.36)、(52.2±5.6) ng/L、(5.2±0.67)μmol/L,均優于對照組治療後的(37.9 ±3.5)ml/m2、(51.1±7.6)mm、(20.7±6.3) mm、(25.2±7.3)、(70.5±31.8)cm/s、(2.85±0.23)、(63.5±1.8)ng/L、(2.55±0.33)μmol/L(t=8.386、-3.856、-4.487、3.867、-1.152、-4.239、12.887、-23.802,均P≤0.05).結論 卡維地洛是治療DCM閤併心理衰竭的有效藥物,能改善患者心功能、冠脈血流儲備能力及內皮功能,效果滿意,值得在臨床推廣.
목적 비교잡유지락여미탁락이치료확장형심기병(DCM)합병심력쇠갈적림상료효.방법 장90례DCM합병심력쇠갈환자안조치료방법불동분위관찰조화대조조,각45례.량조균채용이뇨、확혈관、강심등약물치료,대조조가용미탁락이,관찰조가용잡유지락,련속치료4～6개월.치료전후검측화비교량조환자좌실사혈분수(LVEF)、좌실수축말내경(LVESVI)、좌실서장내경(LVEDVI)、좌심실단축축단솔(FS)、최태봉치혈류속도(hCFV)、관상동맥혈류저비(CFR)、혈청내피소(ET)급일양화담(NO)함량.결과 관찰조치료후LVEF、LVEDVI、LVESVI、FS、hCFV、CFR、ET、NO분별위(44.0±3.4) ml/m2、(45.2±6.9)mm、(20.9±5.4) mm、(30.4±5.3)、(78.2±31.6)cm/s、(3.12±0.36)、(52.2±5.6) ng/L、(5.2±0.67)μmol/L,균우우대조조치료후적(37.9 ±3.5)ml/m2、(51.1±7.6)mm、(20.7±6.3) mm、(25.2±7.3)、(70.5±31.8)cm/s、(2.85±0.23)、(63.5±1.8)ng/L、(2.55±0.33)μmol/L(t=8.386、-3.856、-4.487、3.867、-1.152、-4.239、12.887、-23.802,균P≤0.05).결론 잡유지락시치료DCM합병심리쇠갈적유효약물,능개선환자심공능、관맥혈류저비능력급내피공능,효과만의,치득재림상추엄.
Objective To compare the clinical efficacy of carvedilol and metoprolol in the treatment of dilated cardiomyopathy patients with heart failure (DCM).Methods According to the different treatment method,90 DCM patients with heart failure patients were divided into the observation group and the control group,45 cases in each group.Both groups were given a diuretic,vasodilator,cardiac and other drug treatment,and the control group were added with metoprolol,and the observation group were added with carvedilol.The treatment lasted 4 to 6 months.Before and after treatment,the levels of left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter (LVESVI),left ventricular diastolic diameter (LVEDVI),left ventricular fractional shorteningrate (FS),largest peak velocity (hCFV),coronary flow reserve (CFR),simultaneous detection of serum levels of endothelin (ET) and nitric oxide(NO) content were observed and compared betweon the two groups.Results After the treatment,the levels of LVEF,LVESVI,LVEDVI,FS,hCFV,CFR,ET,NO of the observation group were (44.0 ± 3.4) ml/m2,(45.2 ±6.9)mm,(20.9 ±5.4)mm,(30.4 ±5.3),(78.2 ±31.6) cm/s,(3.12 ±0.36),(52.2 ±5.6) ng/L,(5.2 ± 0.67) μmol/L,respectively,which were better than those of the control group[(37.9 ± 3.5)mL/m2,(51.1 ± 7.6)mm,(20.7 ±6.3) mm,(25.2 ±7.3),(70.5 ± 31.8)cm/s,(2.85 ±0.23),(63.5 ± 1.8)ng/L,(2.55 ± 0.33) μmoL/L] (t =8.386,-3.856,-4.487,3.867,-1.152,-4.239,12.887,-23.802,all P ＜ 0.05).Conclusion Carvedilol is an effective drug for the treatment of DCM consolidated psychological failure,which can improve heart function and coronary flow reserve capacity and endothelial function in patients,which is worth in the clinical with satisfactory results.
